NASDAQ
18.06.26 | 16:25
4,100 US-Dollar
+1,23 % +0,050
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.05. | Foghorn Therapeutics Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.05. | Foghorn Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 27.04. | Stifel reiterates Foghorn Therapeutics stock rating on AACR data | 1 | Investing.com | ||
| 22.04. | H.C. Wainwright reiterates Foghorn Therapeutics stock rating at buy | 1 | Investing.com | ||
| 21.04. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting | 2 | GlobeNewswire (USA) | ||
| 21.04. | Foghorn Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 09.04. | Foghorn to present preclinical cancer data at AACR meeting | 1 | Investing.com | ||
| 09.04. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting | 2 | GlobeNewswire (USA) | ||
| FOGHORN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 17.03. | Citizens reiterates Foghorn Therapeutics stock rating on pipeline progress | 5 | Investing.com | ||
| 12.03. | Foghorn Therapeutics: Jefferies bekräftigt "Buy"-Rating im Vorfeld von Pipeline-Daten | 2 | Investing.com Deutsch | ||
| 12.03. | Jefferies reiterates Foghorn Therapeutics stock rating on pipeline data | 2 | Investing.com | ||
| 12.03. | Stifel reiterates Foghorn Therapeutics stock rating at buy | 2 | Investing.com | ||
| 11.03. | Foghorn Therapeutics GAAP EPS of -$1.18 misses by $0.08, revenue of $30.91M misses by $0.31M | 1 | Seeking Alpha | ||
| 11.03. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook | 227 | GlobeNewswire (Europe) | FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC) Selective CBP degrader program with potential... ► Artikel lesen | |
| 23.02. | Foghorn Therapeutics appoints Ryan Maynard as CFO | 1 | Seeking Alpha | ||
| 23.02. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer | 206 | GlobeNewswire (Europe) | WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases... ► Artikel lesen | |
| 23.02. | Foghorn Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.02. | Jefferies stuft Foghorn Therapeutics mit "Buy" ein und sieht erhebliches Potenzial | 2 | Investing.com Deutsch | ||
| 17.02. | Jefferies initiates Foghorn Therapeutics stock with buy rating | 13 | Investing.com | ||
| 13.01. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium | 283 | GlobeNewswire (Europe) | WATERTOWN, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases... ► Artikel lesen |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 278,30 | +3,07 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| COGENT BIOSCIENCES | 34,690 | +3,03 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an updated objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 91,07 | +1,30 % | Kymera presents KT-621 phase 1 data in Japanese adults | ||
| APOGEE THERAPEUTICS | 88,03 | -0,45 % | Apogee Therapeutics, Inc. - 8-K, Current Report | ||
| TANGO THERAPEUTICS | 29,710 | -7,99 % | Tango Therapeutics auf Rekordhoch: Aktie steigt auf 33,19 USD | ||
| ERASCA | 13,990 | +0,07 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| BEAM THERAPEUTICS | 33,250 | +2,37 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| QIAGEN | 31,925 | -0,87 % | Qiagen-Aktie: Schlafender Riese und Übernahme-Kandidat? | Nach kurstechnisch harten Monaten kämpft sich die Aktie des niederländischen Biotechnologie- und Diagnostikunternehmens Qiagen langsam zurück. Mit Kursen um 32 Euro notiert das Papier noch immer mehr... ► Artikel lesen | |
| CG ONCOLOGY | 61,42 | +1,64 % | CG Oncology Inc.: CG Oncology Reports Positive First Results from CORE-008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients | - High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively - High-Grade - EFS in the overall intention-to-treat... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 25,710 | -1,95 % | Arcutis Biotherapeutics, Inc.: Arcutis' ZORYVE (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines | Strong recommendation with high certainty of clinical evidence underscores proven efficacy, safety, and tolerability of ZORYVE cream as a steroid-free topical phosphodiesterase type 4 (PDE4) inhibitorAtopic... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 35,890 | +3,07 % | Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM) | - No relationship observed between EDG-7500 exposure and LVEF; no LVEF reductions below 50% - - Consistent and clinically meaningful improvements observed in echocardiogram parameters,... ► Artikel lesen | |
| DYNE THERAPEUTICS | 19,780 | +3,02 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc. | - Up to $125 million in additional borrowing capacity provides further strategic flexibility - - $50 million of additional capacity funded at amendment closing - WALTHAM, Mass., June 17, 2026 (GLOBE... ► Artikel lesen | |
| RELAY THERAPEUTICS | 16,100 | +3,47 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Pricing of Public Offering of Common Stock | CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies... ► Artikel lesen | |
| DISC MEDICINE | 70,74 | +0,75 % | Disc Medicine presents trial data for blood disorder treatments | ||
| RECURSION PHARMACEUTICALS | 3,130 | +0,64 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen |
Das Unternehmen FOGHORN THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 4,100 Euro und damit +1,23 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FOGHORN THERAPEUTICS INC finden Sie auf Wallstreet Online.